Archer (part of Integrated DNA Technologies)

About

Archer, a division of Integrated DNA Technologies (IDT) since December 2022, specializes in next-generation sequencing (NGS) technologies for oncology and genomic research. The integration of Archer enhances IDT's offerings in cancer research and comprehensive genomic profiling. Archer provides targeted NGS assays, including FUSION *Plex*™ and VARIANT *Plex*™, designed to detect gene fusions, splice variants, and somatic mutations. Their recent innovations include liquid reagent formulations that improve workflow efficiency. Additionally, Archer's HRD Technology, launched in 2024, assesses homologous recombination deficiency to aid in identifying biomarkers for cancer therapy response. Their automated workflow solutions are compatible with high-throughput platforms, streamlining NGS library preparation. Archer collaborates with partners like Molecular Health to integrate their assays with bioinformatics software, enhancing data analysis for research labs. Geneseeq Canada is an example of a customer utilizing Archer's NGS technologies to advance cancer research and therapeutic discovery.